Acelrx Pharmaceuticals Stock Price To Earnings To Growth
AcelRx Pharmaceuticals fundamentals help investors to digest information that contributes to AcelRx Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of AcelRx Stock. The fundamental analysis module provides a way to measure AcelRx Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AcelRx Pharmaceuticals stock.
AcelRx |
AcelRx Pharmaceuticals Company Price To Earnings To Growth Analysis
AcelRx Pharmaceuticals' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
CompetitionBased on the latest financial disclosure, AcelRx Pharmaceuticals has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Pharmaceuticals sector and about the same as Health Care (which currently averages 0.0) industry. The price to earnings to growth for all United States stocks is 100.0% higher than that of the company.
AcelRx Price To Earnings To Growth Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AcelRx Pharmaceuticals' direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of AcelRx Pharmaceuticals could also be used in its relative valuation, which is a method of valuing AcelRx Pharmaceuticals by comparing valuation metrics of similar companies.AcelRx Pharmaceuticals is currently under evaluation in price to earnings to growth category among its peers.
AcelRx Fundamentals
Return On Equity | -0.51 | |||
Return On Asset | -0.32 | |||
Operating Margin | (28.28) % | |||
Current Valuation | 3.25 M | |||
Shares Outstanding | 16.95 M | |||
Shares Owned By Insiders | 2.63 % | |||
Shares Owned By Institutions | 38.88 % | |||
Number Of Shares Shorted | 508.11 K | |||
Price To Earning | 0.39 X | |||
Price To Book | 0.74 X | |||
Price To Sales | 36.65 X | |||
Revenue | 1.77 M | |||
Gross Profit | (3.34 M) | |||
EBITDA | (30.18 M) | |||
Net Income | 47.76 M | |||
Cash And Equivalents | 22.92 M | |||
Cash Per Share | 3.11 X | |||
Total Debt | 10.42 M | |||
Debt To Equity | 0.43 % | |||
Current Ratio | 1.81 X | |||
Book Value Per Share | 1.08 X | |||
Cash Flow From Operations | (28.33 M) | |||
Short Ratio | 4.56 X | |||
Earnings Per Share | (2.75) X | |||
Target Price | 4.63 | |||
Number Of Employees | 19 | |||
Beta | 0.52 | |||
Market Capitalization | 13.56 M | |||
Total Asset | 47.49 M | |||
Retained Earnings | (425.83 M) | |||
Working Capital | 10.8 M | |||
Current Asset | 118.95 M | |||
Current Liabilities | 12.78 M | |||
Z Score | -13.56 | |||
Net Asset | 47.49 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Other Consideration for investing in AcelRx Stock
If you are still planning to invest in AcelRx Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the AcelRx Pharmaceuticals' history and understand the potential risks before investing.
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Money Managers Screen money managers from public funds and ETFs managed around the world |